Responses
Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
